|

 

Microsoft word - 071204 umkchicklin chair position description revised2.doc

University of Missouri - Kansas City Kansas City, Missouri Merl & Muriel Hicklin/Missouri Endowed Chair: Associate/Full Professor, School of Medicine "UMKC is a strong public research university living the values of Education First, Discovery and Innovation; Integrity and Accountability; Diversity, Inclusiveness and Respect; and Energized Collaborative THE SEARCH The Department of Medicine at the University of Missouri – Kansas City (UMKC) School of Medicine invites nominations and applications for the position of the Merl and Muriel Hicklin/Missouri Endowed Chair. The selected candidate must have a passion for teaching, health care delivery, and outcomes research. S/he must have demonstrated the ability to foster collaboration with other academic divisions, sister institutions within UMKC, and local public health organizations. The Department of Medicine is proud of its diverse faculty, and is an equal opportunity employer. Applications from female and minority applicants are welcome. The selected candidate must be a physician at the associate professor level or above with at least 5 years experience and an accomplished investigator and have a record of ongoing grant support in the area of health outcomes research. S/he should also be an effective mentor to junior faculty in the development of outcomes research. THE UNIVERSITY OF MISSOURI -- KANSAS CITY One of the UMKC's major priorities is to lead in the area of Life and Health Sciences. The $35 million Flarsheim Science and Technology Building opened in 2000, and an additional $40 million has been committed to a new health sciences building. Collaborative initiatives, a center for medical research and the drive of public and private partnerships is quickly making the area a national center for science and health research. UMKC is a partner in the Kansas City Life Sciences Institute, a collaborative venture among the metro area's top research institutions and civic groups as well as some Schools and Departments within the University. The University is now moving aggressively to take advantage of exciting synergistic opportunities for interdisciplinary research both within UMKC and with partners. Historically, UMKC has evolved into a comprehensive, research-intensive university with 13 schools from a small, teaching-oriented institution. UMKC's colleges and programs offer more than 125 degrees, including 49 master's degrees and select doctoral degrees. It enrolls 10,400 students, with an additional 2,300 high school students also taking some university-level classes. Fifty-five percent of matriculated students are undergraduates, 32% are graduate students, and 13% are professional students. UMKC is large enough to provide a broad range of educational and social opportunities, but small enough to retain a sense of community and belonging. It serves traditional and non-traditional students of all ages, and is strongly committed to providing quality education for diverse populations. The average ACT score of entering freshmen is 24.7, which is among the highest of all public research universities nationwide. Approximately 19% of UMKC students are members of a minority group and 7% are international students representing more than 80 countries. The University is located in the center of Kansas City's "cultural zone," a part of the city encompassing several museums, a premier research institute, a renowned science and technical and research library, as well as the Country Club Plaza and Westport shopping and entertainment districts. Located in Kansas City are the headquarters of significant industry leaders such as Sprint, Hallmark, American Century, and H&R Block. These companies provide students with numerous employment options. A high percentage of UMKC graduates (60%) choose to remain in Kansas City upon graduation. During the early 1990's, UMKC launched an aggressive campaign to strengthen its programs and attract top-notch faculty through the Missouri Endowed Chair and Professorship Program. The College of Arts and Sciences has six Curators' Professors, two Distinguished Teaching Professors, and two endowed chairs. Since 1993, 33 endowed chairs and professorships have brought distinguished new teachers and researchers to the campus. The University is committed to increasing research funding and the number of doctoral students, and to improving the physical plant. THE SCHOOL OF MEDICINE History The University of Missouri Kansas City School of Medicine official was founded in 1971 with a unique approach to medical education. Based on a six-year curriculum, the School of Medicine admits students into the program directly from high school. Students graduate with their Baccalaureate-Doctor of Medicine (Baccalaureate/M.D.) from the same institution. The curriculum integrates the liberal arts, and basic and clinical sciences within a team approach to learning. When E. Grey Dimond, MD, was asked to devise an academic plan for a new medical school in the early 1960s, he agreed with one stipulation: "Only if you make it fun." With that in mind, a unique new medical school was created that would provide students with early and continuous patient-care experience. A charter class of 18 students joined 23 "advanced standing" students to begin classes in 1970 at the University's Health-Sciences building and a year later, a group of 40 students became the first official Year 1 class to enter the School. More than 2,000 physicians have since received their MDs from the UMKC School of Medicine. The School officially opened the doors of its current facility at 2411 Holmes Street in the heart of Kansas City's historic Hospital Hill district in August 1974 at a cost of $13.5 million. The School of Medicine is physically connected to Truman Medical Center Hospital Hill, one of its primary teaching hospitals. Children's Mercy Hospital and the Western Missouri Mental Health Center are located nearby in the Hospital Hill area. Saint Luke's Hospital of Kansas City is about two miles from the School, located near Kansas City's Country Club Plaza district. Truman Medical Center Lakewood is located on the east side of Kansas City. Other affiliated hospitals that provide clinical experience include Baptist Medical Center, Menorah Medical Center, Research Medical Center and Trinity Lutheran Hospital. The growth of the School of Medicine extends to graduate medical education, in which the School now offers residency programs in 13 specialty areas and training in 20 subspecialty residency programs. More information about the School of Medicine may be found at http://www.med.umkc.edu/. The Liaison Committee on Medical Education, a national body representing the Association of American Medical Colleges and the American Medical Association, has endorsed the School of Medicine and its academic philosophy. The School of Medicine is fully accredited by the LCME. The School of Medicine and Truman Medical Centers recently received the prestigious designation as a National Center of Excellence in Women's Health from the U.S. Department of Health and Human Services (DHHS), becoming the only Center in a four-state region and one of only 21 such centers nationwide. School of Medicine Clinical/Academic Departments The School of Medicine has 15 departments: Anesthesiology, Basic Medical Science, Clinical Pharmacology, Community & Family Medicine, Emergency Medicine, Internal Medicine, Obstetrics & Gynecology, Ophthalmology, Oral & Maxillofacial Surgery, Orthopaedic Surgery, Pathology, Pediatrics, Psychiatry, Radiology and Surgery. The school has five key partner hospitals: Children's Mercy Hospital, Saint Luke's Hospital of Kansas City, Truman Medical Center Hospital Hill, Truman Medical Center Lakewood, and Western Missouri Mental Health Center. Faculty The School has 570 full-time and 670 volunteer faculty positions, 375 residents and fellows in 32 ACGME sponsored programs. Faculty rank and years at UMKC are listed below in Appendix B. Please also refer to the attached organization chart for the School of Medicine, located in Appendix B. The School of Medicine Office of Research One of the highest priorities in the School of Medicine's strategic plan is to improve the research infrastructure to support the needs of existing faculty, to aggressively recruit new NIH-funded investigators, and to expand research training opportunities for medical students and residents. The UMKC School of Medicine has a diversity of biomedical research strengths enabling it to provide leadership in research at UMKC. Since medicine is at the very heart of all biomedical research efforts, the School's role is critical for UMKC to achieve maximal productivity from its life sciences research. Our clinical affiliates provide knowledgeable and productive clinical faculty to enhance research programs, as well as access to patients from diverse demographic backgrounds presenting a wide variety of clinical conditions. Cooperation with other UMKC professional schools, such as Nursing and Pharmacy, with all clinical affiliates, and with the Kansas City Area Life Science Institute, the Stowers Institute, and the Midwest Research Institute, provides additional opportunities for faculty and students. For example, there is an emerging strength in outcomes research incorporating faculty from the School of Medicine, College of Arts and Sciences, College of Dentistry, and the School of Computer Science and Engineering. Endowed Chair Program One of the great strengths of the School of Medicine is its Endowed Chair program. The School has jointly recruited 18 Endowed Chairs in collaboration with its affiliated hospitals. These Chairs provide an established nexus for highly productive translational research, which has led to an overall increase in Federal funding, and foundation and industry-sponsored research. Future Growth Important new facilities are in the building or planning phases. The School of Medicine's strategic plan calls for total renovation of animal facilities on Hospital Hill, renovation of 15,000 square feet of laboratory space, and acquisition of core scientific equipment necessary to support modern scientific research. In addition, a new Health Sciences Building is in the final stages of architectural design. This new complex, on which construction is expected to begin during 2005, will house the Schools of Pharmacy and Nursing and research programs from selected Hospital Hill stakeholders. Department of Medicine The Department of Medicine represents four primary organizations: the University of Missouri – Kansas City School of Medicine, the Truman Medical Centers, the St. Luke's Hospital of Kansas City, and the University Physician Associates. The Department members serve as faculty in the educationally innovative medical school. Most students enter this program after secondary school and will earn both baccalaureate and medical degrees in six years. Beginning in the third year of medical school, while they continue required class work, students help care for patients in the outpatient and inpatient settings in small academic units called docent teams composed of twelve students and one faculty member (docent) from the Department of Medicine. Students remain with their docent team for the last four years of the six-year program. This docent system emphasizes collegiality and a team approach to learning and patient care. The docent system provides a longitudinal mentorship for our students. More information about the residency program (which is one of a number post-graduate, university-based programs) can be found at http://www.med.umkc.edu/residency/intmed/. Truman Medical Center (previously Kansas City General Hospital) has served as a center of clinical excellence and medical education for over 125 years. The Department of Medicine at Truman Medical Center offers outstanding care in General Internal Medicine as well as the specialty areas of Allergy-Immunology, Cardiology, Endocrinology, Gastroenterology, Hematology-Oncology, Infectious Disease, Nephrology, Neurology, and Respiratory-Critical Care Medicine. Saint Luke's Hospital is a 650-bed not-for-profit tertiary referral center with a network of 550 skilled physicians that represent more than 56 medical specialties. Saint Luke's Hospital was founded in 1882, and since has grown to cover more than eight square blocks and include more than a dozen major facilities. The Primary Care General Internal Medicine Residency Track, directed by Dr. Brent Beasley, was recently funded by a HRSA Residency Training in Primary Care grant to develop, expand, and maintain an innovative approach to teaching and learning Primary Care General Internal Medicine. The track currently has four residents, and will be expanding to eight residents over the course of the grant (7/03-6/06). Our first two residents graduated in May of 2004 and now work in underserved rural areas. University Physician Associates is the not-for-profit professional corporation for the clinical faculty of the University of Missouri – Kansas City School of Medicine and Truman Medical Center. This organization oversees faculty benefits, retirement, practice-efficiency, and patient-care billing. The Department of Medicine is a vibrant community of medical scholars, practitioners and educators, operating through the four organizations just discussed. The Department strives to provide patients, trainees, and the medical community with outstanding clinical care, teaching, and clinical research. George Robert Reisz, M.D. is the Chairman of the Department of Medicine. He has been a professor since 1998 and Chairman since 2000. Dr. Reisz undergraduate education was completed at Vanderbilt University and he received his M.D. at Indiana University School of Medicine. He completed his residency in Internal Medicine at the University of Missouri-Kansas City (UMKC) School of Medicine and Truman Medical Center followed by a fellowship in Pulmonary Medicine also at UMKC. Dr. Reisz's professional certifications include the American Board of Internal Medicine certification in the specialty of Internal Medicine and the subspecialties of Pulmonary Disease and Critical Care. Informatics The UMKC School of Medicine will establish a Department of Informatic Medicine and Personalized Health. The department will provide an organizational infrastructure to fulfill the education, research, and service needs in informatic medicine of the School of Medicine, and to position the School of Medicine as a leader and a strategic partner in life sciences in Kansas City and Missouri. The UMKC School of Medicine has been allocated recurring funds and non-recurring funding for the informatic medicine strategic initiative1, which is closely aligned with the new UMKC-wide masters degree program in bioinformatics. As such, the Hicklin Chair holder will have numerous opportunities to contribute to the informatics efforts to the benefit of the UMKC research enterprise at the department, school, and university levels. 1 The specific goals and measures of success associated with this initiative can be found in Appendix A. UMKC is well along in the process of establishing a Masters degree in bioinformatics that builds upon UMKC core strengths and offers an interdisciplinary program to meet local, state, and national needs. Bioinformatics is, by definition, an interdisciplinary field, employing a diverse array of resources and expertise. It is an enabling technology that provides the tools and methods essential for organizing, analyzing, and generating new knowledge from data in the life and health sciences. Rapid advances in computer technology and their application to analyzing the vast amounts of data generated in the health and life sciences hold great promise for economic development and social benefits. The Masters program is built on an interdisciplinary model and will utilize the faculty expertise, course work, and research offered by several departments and schools within the university. Students enrolling in the program will be able to select from among the three emphasis areas, each stressing skill sets and applications appropriate to the subfield within the broad area of bioinformatics: • Computational Bioinformatics • Genomic Bioinformatics • Medical Informatics A core curriculum provides all students with a foundation of knowledge and tools in the fields of mathematics, computer sciences, and biological sciences, after which students complete courses in their chosen emphasis area. A thesis option is available for those students wishing to conduct research as part of their degree program. Graduates of the program are expected to be able to develop and apply computational tools to a variety of problems in the health and life sciences that require the use of biological, behavioral, health, or medical data. Graduates are also expected to demonstrate competencies in assessing needs and implementing computing technologies to support teaching and research environments at a high level, and to be effective team members who can contribute to multidisciplinary approaches in the field of bioinformatics. Outcomes Research at UMKC UMKC School of Medicine is committed to grow its presence in outcomes research. Several specific areas outcomes research are well established, thereby offering collaboration opportunities for the Endowed Chair holder, should his/her research interests be so aligned. These areas include: cardiovascular outcomes research, lung outcomes research, bone biology (mineralized tissue) outcomes research and HIV outcomes research. Cardiovascular Outcomes Research UMKC's Section of Cardiovascular Outcomes Research is one of the country's pre-eminent programs examining patient-, provider- and system-level characteristics associated with patient outcomes. In particular, the research teams at the Mid America Heart Institute have been interested in patient-centered outcomes, economics, decision analysis and quality of care. They have been very active in the design of clinical trials, the execution of prospective registries and the definition of healthcare quality. The Mid America Heart Institute is one of only three centers in the United States that are approved to analyze the American College of Cardiology's National Cardiovascular Data Registry, the nation's largest series of prospective registries in the area of cardiovascular disease. On average, over $4 million/year of extramurally-funded research is generated by UMKC's cardiovascular outcomes researchers. Important emerging activities include two ends of the translational research spectrum. First, UMKC CV outcomes researchers are collaborating with basic scientists throughout the country, including Washington University, the University of Iowa, Yale University and the University of Texas-Austin, to leverage our observational, outcomes-oriented registries in order to define the incremental clinical importance of new genetic and biomarker discoveries. At the other end of the spectrum, UMKC facuulty are developing novel information technology (IT) solutions so that complex, multivariable predictive models can be executed with patient-specific data at the interface of clinical care; this enables individualized, evidence-based medical decisions to be made that are tailored to the individual goals and expectations of individual patients. This infrastructure in study design, database development, statistical analyses, qualitative and implementation research and methodological development should be a rich resource from which the successful Hicklin Endowed Chair candidate can accelerate their own research program as well as nurturing the careers of other UMKC faculty. One current effort in CV outcomes research is the National Institutes of Health-awarded Saint Luke's Mid America Heart Institute and Washington University in St. Louis program. This program has been given more than $15 million in a Specialized Center for Clinically Oriented Research (SCCOR) grant to fund a five-year, multi-center study of patients recovering from heart attacks. John Spertus, MD, MPH, FACC, professor of medicine at UMKC and director of cardiovascular outcomes research at Mid-America Heart Institute2, will lead the clinical portion of the grant. This study, which began the first of the year 2005 and ends in December 2009, will marry the basic science expertise of Washington University in St. Louis, led by principal investigator Daniel Kelly M.D., with the clinical outcomes strengths of Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City (UMKC). The two primary goals of the project are to eliminate the excess burden of myocardial disease in diabetic patients, and to define and characterize racial disparities in outcomes of patients with heart attacks. Lung Outcomes Research Lung Research Center Background In 1999 UMKC School of Medicine in partnership with Truman Medical Center and Children's Mercy Hospital established the Kansas City Asthma Clinical Research Center (ACRC) funded by a $500,000 grant over five years from American Lung Association 2 A summary of selected studies and databases from the Outcomes Research Group at UMKC / Mid America Heart Institute can be found in Appendix C. (ALA). The ACRC is one 20 centers nationwide undertaking a multi-center research approach to discovering improved methods to manage asthma with the long-term goal to find a cure for asthma. UMKC joins Johns Hopkins, Duke, Washington University in St. Louis, and many other prestigious universities in the largest industry independent research consortium to ever study asthma. The first project involved the study of the safety of the influenza vaccine in over 2000 adults and children with asthma. The results of that study were published in the New England Journal of Medicine in 2001. The next study evaluated the effectiveness of a theophylline in asthma. The ALA increased funding to $750,000 for the UMKC ACRC program for another five years starting in July 2004. The Lung Center is collaborating with UMKC's department of Informatic Medicine and Personal Health in smoking cessation research. Collaboration with the School of Pharmacy in evaluating heparin containing microparticles for pulmonary delivery is ongoing. The Lung Center is also collaborating with Lanny Rosenwasser M.D. and Jay Portnoy, M.D. at Children's Mercy Hospital in asthma research. Lung Research Center 2006-07 Grants • American Lung Association: Asthma Clinical Research Center: Grant Renewed 2004-2009 for $750,000. (Salzman- Principal Investigator) • The Leukotriene Modifier Or Corticosteroids Trial (The LOCS Trial) - A Comparison of Continued Low-Dose Inhaled Corticosteroids versus Leukotriene Modifier for Asthmatic Patients Well Controlled with Low Dose Inhaled Corticosteroids. Funding from GlaxoSmithKline $4,633,888 total funding over 5 years to Asthma Clinical Research Centers 2001-2006 One of 19 principal investigators (Salzman) • The Trial of Asthma Patient Education, Funding from National Heart, Blood and Lung Institute $2,570,617 total funding over 4 years to Asthma Clinical Research Centers 2002-2006. One of 19 principal investigators (Salzman) • Study of Acid Reflux in Asthma, Funding from National Heart, Blood and Lung Institute $3,800,627 total funding over 5 years to Asthma Clinical Research Centers 2004-2009. One of 19 principal investigators (Salzman) • Study of Acid Reflux in Childhood Asthma, Funding from National Heart, Blood and Lung Institute $2,414,841 total funding over 5 years to Asthma Clinical Research Centers 2007-2012 One of 20 principal investigators (Salzman and Dinakar) • Missouri Hospital Association Regional Health Partnership Grant for Asthma Education and Research Programs- $100,000; 2002-2006. Principal Investigator (Salzman) • Blue Cross and Blue Shield of Kansas City: $49,875. Developing a culturally tailored smoking cessation program for heavily addicted Chronic Obstructive Pulmonary Disease (COPD) patients; Co-Principal Investigator 2007-2008 (Salzman, Poston, Haddock) Lung Research Center 2006-07 Grant Applications • BC Youan, B. Herndon, GA Salzman. R-15 proposal to NIH submitted in Feb. 2007, "Heparin containing Microparticles for Pulmonary Delivery" (not funded) • L Rosenwasser, GA Salzman. NIH proposal for "Functional Neurological Changes on Imaging Studies Associated with Asthma Exacerbations" (not funded) Lung Research Center 2006-07 Presentations • Mador M.J, Choi Y, Braun M, Bhat A et al. Relation between Body Position, Sleep Stage and Respiratory Events in Patients with Suspected Obstructive Sleep Apnea. ATS 2007 San Francisco International Conference. • T. Ardiles, B. Herndon. Pleurodesis Model with Three Sclerosants-What can Serum Tell us About the Mesothelial cell? ATS 2007 San Francisco International Conference. • JC Graff, GA Salzman, SL Thomas. Airway pressure Release Ventilation: Preliminary Experience in a Medical Intensive Care Unit. CHEST 2006 International Conference Salt Lake city Utah. CHEST October 2006;130 (4):134S. • Martires J, Svetlecic J, Yacoub W, Molteni A, Quinn T, Herndon B. Pulmonary gelatinases in lung bronchiolitis models. FASEB J. 21(6) A184, abstract 374.9, April 2007 • J. Svetlecic, J. Martires, B. Herndon, "Pulmonary Gelatinases in the Remodeling of Bronchiolitis Obliterans" CHEST, international meeting of Pulmonary physicians, (J. Svetlecic won "outstanding young investigator for Chest, 2006" with this presentation) Nov. 2006 • Martires, J., Svetlecic J, Molteni A, Quinn T, Herndon B. "Pulmonary Gelatinases in Lung Bronchiolitis Models" UMKC School of Medicine Student Research Day, April 20, 2007 p 7 • Waghela, Nihir, "Effects of Pulmonary Urease on the Cellular Response to H. pylori Protein Coated Beads" UMKC School of Medicine Student Research Day, April 20, 2007, p 12 Lung Research Center 2006-07 Publications • Howell GH, Salzman G Clinical Review: Use of Bronchodilators in Chronic Obstructive Pulmonary Disease. Hospital Physician October 2006:27-34. • Young DJ, Salzman GA. Status Asthmaticus in Adult Patients. Hospital Physician Nov. 2006:13-19. • The American Lung Association Asthma clinical Research Centers (including GA Salzman). Clinical Trial of Low-dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. AJRCCM 2007. 175:235-242 • The American Lung Association Asthma Clinical Research Centers (including GA Salzman). Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. N Eng J Med 2007; 356:2027-2039 • Salzman GA. Smoking Ruins, The Prevention of Lung Disease. Missouri Medicine 2007; 104 (3): 208-209. • Khan ZU, Salzman GA. Management of Sepsis: The Surviving Sepsis Guidelines for Early Therapy. Hospital Physician 2007; 55:21-30. Bone Biology Outcomes Research The Mineralized Tissue Team is led by Lynda Bonewald, Ph.D., an Endowed Professor in Oral Biology, Hong Wen Deng, Ph.D., an Endowed Chair in Orthopedics Research, and Richard Derman M.D. an Endowed Chair in Women's Health. The team consists of researchers and clinicians focusing on the skeleton and oral/craniofacial biology. Clinical bone research at UMKC and its affiliated hospitals is multidisciplinary (headed by Drs. Jim Hamilton, Endowed Chair in Orthopaedic Surgery, and Richard Derman) and includes the disciplines of orthopedic surgery, endocrinology, pediatrics, gynecology, radiology and dentistry. During the past 24 months, a strong externally-funded research base has allowed investigators at UMKC to focus on indices of bone strength, aspects of bone healing, the effects of estrogens, progestin's, selective estrogen receptor modulators (SERMS), and three bisphosphonates on bone mineral density and fracture outcomes. In addition, these researchers have examined response to therapy, drug tolerability, and aspects of life quality. Other clinical bone research investigations include postpartum medroxyprogesterone acetate use and maintenance of bone mass in an African-American population, and endometriosis as a variable in the treatment and outcomes of bone loss in women. Very recently, the SOM received a $5.7 million dollar SCOR grant to study the genetics of osteoporosis. Dr. Bonewald is Director of the Bone Biology Research Program within the School of Dentistry, which includes Drs. Mark Johnson, Jeff Gorski, Sarah Dallas, and Shiva Kotha. Other experienced investigators in mineralized tissue in Oral Biology include Drs. David Eick and Larry Katz. Dr. Donna Pacicca, a pediatric orthopedic surgeon at Children's Mercy Hospital, is also a member of this team. Numerous collaborations have already been established with investigators in the School of Computing and Engineering, Children's Mercy Hospital, Midwest Research Institute, and Kansas University Medical Center. Many additional opportunities exist for training within this program, which has successfully integrated the areas of genomics, proteomics, transgenic technology, and bioinformatics into its graduate studies. HIV Outcomes Research UMKC has a long history of clinical research in HIV. UMKC faculty members led the development of the Kansas City AIDS Research Consortium, which was a community based organization that focused on clinical trials of retroviral agents, prevention of opportunistic infections, treatment of opportunistic infections and initial studies of prevention vaccines. Targeted areas included prevention and management of opportunistic infections unique regionally (histoplasmosis and M. kansasii), but evolved to become active in the development of some of the first highly active retroviral regimens. As the HIV epidemic has matured, we have focused our attention to problems associated with HIV that are more concentrated among people living in poverty, in difficult to reach populations, and among minority groups and women. Efforts over the last three years include studies involving motivational counseling to improve HIV medication adherence, done in conjunction with the UMKC Department of Psychology funded with an ongoing NIH R01 grant, studies on prevention of HIV through counseling of safe sex practices by HIV infected clients funded by a recently completed Centers for Disease Control and Prevention grant, and initial studies evaluating the large number of the HIV infected population that are out of care. HIV publications 1993 to present by UMKC ID section: • BAMBERGER DM, Driks MR, Gupta MR, et al. Mycobacterium kansasii in patients with the human immunodeficiency virus in Kansas City. Clin Infect Dis, 18:395-400, 1994. • Wheat J, S MaWhinney, R Hafner, D McKinsey, D Chen, A Korzun, KJ Skahan, P Johnson, R Hamill, D BAMBERGER, P Pappas, J Stansell, S Koletar, K Squires, RA Larsen, T Cheung, N Hyslop, KK Lai, D Schneider, C Kauffman, M Saag, W Dismukes, W Powderly for the NIAID AIDS Clinical Trials Group and the Mycoses Study Group. Treatment of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med, 103:223-32, 1997. • McKinsey DS, LJ Wheat, GA Cloud, M Pierce, JR Black, DM BAMBERGER, M Goldman, CJ Thomas, HM Gutsch, B Moskovitz, WE Dismukes, CA Kauffman, and the NIAID Mycoses Study Group. Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: Randomized placebo-controlled double-blind study. Clin Infect Dis, 28:1049-56, 1999. • Hajjeh RA, PG Pappas, H Henderson, D Lancaster, DM BAMBERGER, KJ Skahan, MA Phelan, G Cloud M Holloway, CA Kauffman, LJ Wheat and the NIAID Mycoses Study Group. Multicenter, case-controlled study of risk factors for histoplasmosis in HIV-infected persons. Clin Infect Dis, 32:1215-20, 2001. • Johnson PC, LJ Wheat, GA Cloud, M Goldman, D Lancaster, DM BAMBERGER, WG Powderly, R Hafner, CA Kauffman, WE Dismukes, and the NIAID Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med, 137:105-109, 2002. • McMahon D. Lederman M. Haas DW. Haubrich R. Stanford J. Cooney E. Horton J. Kelleher D. Ross L. Cutrell A. Lee D. Spreen W. Mellors JW. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antiviral Therapy. 6(2):105-14, 2001 Jun. • Leoung GS. Stanford JF. Giordano MF. Stein A. Torres RA. Giffen CA. Wesley M. Sarracco T. Cooper EC. Dratter V. Smith JJ. Frost KR. American Foundation for AIDS Research (amfAR) Community-Based Clinical Trials Network. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. Journal of Infectious Diseases. 184(8):992-7, 2001 Oct 15. • Lederman MM. McKinnis R. Kelleher D. Cutrell A. Mellors J. Neisler M. Cooney E. Haas DW. Haubrich R. STANFORD J. Horton J. Landay A. Spreen W. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 14(17):2635-42, 2000 Dec 1. • Staszewski S. Morales-Ramirez J. Tashima KT. Rachlis A. Skiest D. STANFORD J. Stryker R. Johnson P. Labriola DF. Farina D. Manion DJ. Ruiz NM. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine. 341(25):1865-73, 1999 Dec 16. • McKinsey DS. Spiegel RA. Hutwagner L. STANFORD J. Driks MR. Brewer J. Gupta MR. Smith DL. O'Connor MC. Dall L. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clinical Infectious Diseases. 24(6):1195-203, 1997 Jun. • Marinac JS. STANFORD JF. A severe hypersensitive reaction to trimethoprim- sulfamethoxazole in a patient infected with human immunodeficiency virus. Clinical Infectious Diseases. 16(1):178-9, 1993 Jan. • WRIGHT JM. Current strategies in the prevention and management of MAC in HIV-infected patients. Pharmacotherapy 1998;18:738-47. • SALKIND AR. Acute delirium induced by intravenous trimethoprim- sulfamethoxazole therapy in a patient with the acquired immunodeficiency syndrome. Human & Experimental Toxicology. 19(2):149-51, 2000 Feb. HIV-Related Grants: • MSG 36. Multicenter case control study of risk factors for histoplasmosis in patients with HIV. Sponsors: NIAID Mycoses Study Group and the Centers for Disease Control and Prevention. $3000, funded in 1997. • ACTG 323/MSG 40. A phase IV randomized study of the use of fluconazole as chronic suppressive therapy versus episodic therapy in HIV positive subjects with recurrent oropharyngeal candidiasis. Sponsor: Pfizer, AIDS Clinical Trial Group, NIAID Mycoses Study Group. $20,000, funded in 1997. • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients with Late-Stage HIV Disease. Sponsor: OxoChemie. $40,000, funded in 1999. • AG1549-504, A randomized, double blind, placebo controlled study of AG1549 in combination with nelfinavir and combivir (zidovudine and lamivudine) in treatment-naive HIV-infected patients. Sponsor: Agouron. $25,000, funded in 1999. • MSG 36. Multicenter case control study of risk factors for histoplasmosis in patients with HIV. Sponsors: NIAID Mycoses Study Group and the Centers for Disease Control and Prevention. $3000, funded in 1997. • ACTG 323/MSG 40. A phase IV randomized study of the use of fluconazole as chronic suppressive therapy versus episodic therapy in HIV positive subjects with recurrent oropharyngeal candidiasis. Sponsor: Pfizer, AIDS Clinical Trial Group, NIAID Mycoses Study Group. $20,000, funded in 1997. • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients with Late-Stage HIV Disease. Sponsor: OxoChemie. $40,000, funded in 1999. • AG1549-504, A randomized, double blind, placebo controlled study of AG1549 in combination with nelfinavir and combivir (zidovudine and lamivudine) in treatment-naive HIV-infected patients. Sponsor: Agouron. $25,000, funded in 1999. • Community-Based Clinical Trials Network, American Foundation for AIDS Research, $669,578, funded 1994-97. • A randomized, multicenter, double-blind, phase three, parallel study of zidovudine alone, versus ZDV plus zalcitabine (DDC) vs ZDV plus saquinavir vs ZDV plus DDC plus saquinavir in previously untreated or minimally pretreated HIV infected patients with CD4 >50, <350. Hoffmann-LaRoche, $134,000, funded 1995. • Optional, open-label, extended use delavirdine mesylate treatment in triple combination for HIV-1 positive patients who participated in other delavirdine mesylate protocols. Upjohn, $40,500. • Phase II Trial.of 1592U89 in combination.in HIV-1 infected patients. Glaxo Wellcome, $78,000, funded in 1997. • Phase III . study of . DMP-266. in HIV infected patients. DuPont Merck, $200,000, funded in 1997. • ART Adherence: Enhanced Counseling and Observed Therapy. To determine whether enhanced counseling with or without observed therapy increases adherence to antiretroviral therapy (ART) compared to standard care. NIH/NIMH/NIDA/NIAAA R01 PA-01-073 funded $2.3 million 1/04 – 12/08 • IDSA/CDC Recommendations for Incorporating HIV Prevention into the Medical Care of HIV-Infected Persons. To implement and evaluate the CDC/IDSA guidelines. 2003-N-00897, funded $500,000 10/03-06/06. CDC. • AIDS community outreach to improve HIV/AIDS services at Truman Medical Center by providing HIV-infected patients and their families, at -risk patients, and caregivers Internet access to HIV/AIDS information. NLM 99-055/SLF/NIH. 09/30/99-03/31/01 CHALLENGES AND OPPORTUNITIES FOR THE ENDOWED CHAIR The Merl and Muriel Hicklin/Missouri Endowed Chair will have many challenges and opportunities at the UMKC School of Medine. Among these, the Chair will be expected to: Mentor younger faculty in the Department of Medicine to build upon and enhance research in the Department. It will be critical that this individual has a demonstrated track record in this regard. Cross traditional boundaries by collaborating with other hospitals, Schools inside and outside UMKC, local public health agencies, and others to promote interdisciplinary and tnter-agency research. Work with various community agencies to promote research that addresses the health needs of underserved populations in the region. Collaborate with other Schools within UMKC, such as the School of Computing and Engineering, the College of Arts & Sciences3 and the School of Biological Sciences, in the development of the currently evolving Informatics program. Tap into existing federal funding sources while seeking additional opportunities at the state and local levels. RESPONSIBILITIES OF THE POSITION The Merl and Muriel Hicklin/Missouri Endowed Chair and leader will conduct and promote outcomes research for the Department of Medicine. This will entail effective and efficient performance of many functions including: • Providing leadership in outcomes research among key constituents within the School of Medicine, as well as external policy makers, civic organizations, and faculty. • Serving as an innovative visionary in outcomes research. • Securing federal and regional extramural financial sponsorship to support outcomes research. • Providing strategic and tactical direction in the conduct of outcomes research. • Integrating outcomes research across disciplines. • Providing outcomes research expertise to healthcare agencies in the community, particularly in the area of the health care needs of the underserved. • Tapping into existing federal funding sources while seeking additional opportunities at the state and local levels. • Seeking ongoing fundraising from a variety of government (local, regional and federal), institutional and corporate sources. 3 In particular, the Health Research Group in the Department of Psychology. • Encouraging partnerships and collaborations with other research institution, public and private agencies, corporations and community-based groups. • Communicating and disseminating research findings. CHARACTERISTICS OF THE IDEAL CANDIDATE The ideal candidate for this position will personify the mission and vision set forth by UMKC, the School of Medicine and the Department of Medicine. While it is realized that no candidate will possess all desired qualities, the ideal candidate: • Must be a physician immediately eligible for tenure at the associate professor • Must have at least 5 years experience as an accomplished investigator with a record of ongoing grant support for research in an area of concentration that is complementary to outcomes research currently being carried out at UMKC. • Will have proven skills and experience in achieving grants and promoting organizational priorities and commitments. • Will be an effective mentor to junior faculty in the development of outcomes • Must have a passion for teaching, health care delivery, and outcomes research. • Must have demonstrated ability to foster collaboration with other academic divisions, sister institutions within UMKC, and local public health organizations. • Develops and commands mutual respect with decision-makers, funders, and other stakeholders, preferring a collaborative, partnering, team-oriented, inclusive approach. • Embodies creativity, flexibility, charisma, practicality, resilience and energy while being able to maintain a big picture orientation. • Is entrepreneurial, proactive, action and results-oriented. • Is a builder of high-leverage, enduring partnerships and alliances. • Is visible within the community and operates in a manner that is community- driven as well as responsive and reactive to policy-makers. • Consistently demonstrates excellent management skills. • Possesses excellent quantitative and analytical skills with the ability to evaluate the differentiated effect of alternatives being pursued. • Demonstrates superior advocacy skills, which s/he has a track record of The search committee is accepting applications immediately and will continue until the position is filled. Please send CV with cover letter, preferably by email, in strict confidence to: The Hollander Group Phone: 202-486-9097 The University of Missouri, Kansas City is an Equal Opportunity Employer and encourages a diverse pool of candidates for this search. School of Medicine Objectives To prepare graduates to enter and complete graduate programs in medical education, qualify for medical licensure, provide competent medical care, and have the educational background necessary for lifelong learning in order to address the health care needs of our state and nation; To implement a model of medical education that: Integrates the humanities, social sciences, basic sciences, and clinical medicine throughout a combined baccalaureate/MD degree curriculum; Is built around a docent system in which a physician-scholar serves as teacher, role model, advisor, counselor, and ombudsman for a small group of students; Permits continuous assessment of student progress; Emphasizes problem-solving and active learning techniques; Demonstrates a multidisciplinary approach to patient care; Encourages the admission and retention of qualified students from diverse backgrounds To be cost-effective by: o Drawing upon faculty in the university's School of Biological Sciences and College of Arts and Sciences o Employing non-tenured clinical faculty o Utilizing community physicians as volunteer clinical faculty and using a diverse set of community facilities and hospitals as major educational sites; To provide a scholarly base for quality patient care; To advance research programs in clinical medicine, basic sciences and medical education; To support, coordinate, and monitor residency and fellowship programs of high quality in affiliated hospitals; and, To encourage faculty to develop continuing medical education programs for internal and external constituencies. Appendix B: School of Medicine Goals for the Masters Degree in Bioinformatics The specific goals of the department are listed below. The specific measures are in the following table. Education. The department and its faculty will develop and deliver educational programs to train the workforce of the future in medicine and life sciences who can effectively utilize biocomputing and informatic technologies to improve the health of individuals and the community. Specific education programs will be as follows: • Medical student education in use of informatics for patient care, patient safety, performance improvement, life-long learning, and application of genomics. • Resident education in use of informatics for patient care, patient safety, performance improvement, life-long learning, and application of genomics. • Masters level graduate program in informatic medicine. • Interdisciplinary doctoral level program in informatic medicine. • Clinical research training program in health research (either masters degree or certificate program). • Continuing medical education (CME) for practicing physicians. Research. The department and its faculty will perform research in the application of computational technology to health science, especially the interface between scientific innovation and the direct care of patients. The following areas of research will be emphasized: • Application of scientific innovations, especially in genomic medicine, to clinical practice. • Use of patient-generated data in health outcomes research. • Application of population and scientific data to care of individual patients (i.e. personalized health). • Development and application of new bedside technologies. • Evaluation of education outcomes (i.e. medical education research). Partnerships. The department and its faculty will develop interdisciplinary partnerships in the following areas: • Scientific partnerships will be fostered between the SOM and other health science schools (Dentistry, Pharmacy, Nursing, Biological Sciences) and the School of Computing and Engineering. • Behavioral science partnerships will be fostered between the SOM and the College of Arts and Sciences. • Entrepreneurial and intellectual property partnerships will be fostered with the Bloch School of Business and Public Administration and the School of Law. In particular, the department will promote a climate of "academic entrepreneurship," in which consideration of the application of innovation is encouraged at the inception and throughout the implementation of study protocols. Faculty Structure. The department will provide an organizational home for research faculty in the School of Medicine, and leverage the resources currently devoted to the Missouri Match Endowed Chairs. • New faculty recruited to the department will hold regular faculty appointments, and submit all federal and foundation grants through the SOM. • The missions of at least three of the existing Missouri Match endowed chairs will be linked to this department. Year 1 (April 2006) Year 3 (April 2008) Medical Students Medical students Formal competency- All students measured learn informatic based curriculum in on competencies in medicine informally informatic medicine informatic medicine Formal competency All residents measured informatic medicine based curriculum in on competencies in informally, or by informatic medicine informatic medicine developed, which crosses disciplines Graduate degrees Masters degree in Doctoral program in informatic medicine informatic medicine Clinical research scholar training (either masters or certificate program) No formal program informatic medicine $14.1 M in FY2004 10% increase in extramural research extramural research grants/contracts $3.6 M in FY2004 All endowed chairs Year 1 (April 2006) Year 3 (April 2008) filled, with three related to informatic Medical Education Research in At least two grants Funded programs in Medical Education submitted for funding medical education and Office in place with national reputation National presentations at medical education meetings. Manuscripts submitted Formal strategic plan Three interdisciplinary relationships with in informatic grants submitted in interdisciplinary translational research teams built around Two interdisciplinary relationships with Formal strategic plan grants submitted in behavioral science around health interdisciplinary team Entrepreneurship/IP No relationship in areas of focus Culture of "academic entrepreneurship" with Bloch school and applications considered in research planning represented on research council Department Chair Interdisciplinary selected and 3 regular department with 10 faculty appointed representing clinical science, behavioral science, computer science, and related Year 1 (April 2006) Year 3 (April 2008) All chairs filled Evaluate any new openings in endowed chairs for congruence with research mission One filled position At least three chairs related to informatic Total publications Implement Faculty Increase related publications by 25% System for all full-time faculty Appendix C: Selected Studies and Databases from Outcomes Research Group of the UMKC / Mid America Heart Institute Background After completing his cardiology fellowship, John Spertus, MD, MPH, FACC began his work with UMKC and the Mid America Heart Institute in 1996. Leveraging the unique research environment at UMKC/Mid America Heart Institute and the opportunities for innovative and opportunistic program development, he has been able to create a nationally renowned cardiovascular outcomes program. He has successfully secured over $15 million in extramural support over the past 8 years and currently employs a research support staff of 2.5 biostatisticians, a programmer/analyst, 2.5 data collectors and an RN PhD project manager and researcher. Previous Studies and Databases: • The Post-Revascularization rEcovery StudieS (PRESS): An 18-month consecutive cohort of 2,326 patients undergoing either PCI (n=1636) or CABG (n=690) at the Mid America Heart Institute. Detailed clinical, procedural and 1-year outcomes data, including several health status measures, are available for analysis. A subset of 495 patients has monthly health status assessments to document the rate of post-procedure recovery. This complete dataset including follow-up is available for analyses. • INvestigation oF Outcomes from acute coronary syndRoMes (INFORM) Project: This AHRQ-sponsored R-01 grant extends the work begun with PRESS by moving from a procedure-oriented registry to a clinical syndrome. An 18-month consecutive registry of all patients presenting to the Mid America Heart Institute or Truman Medical Center, Kansas City's County Hospital, with an acute coronary syndrome were enrolled. Over 1,000 baseline data elements were collected along with 1-, 6-, and 12-month health status and clinical outcomes data are available. • Kansas City Cardiomyopathy Questionnaire (KCCQ) Interpretability Study: This is a 14-center prospective registry of 546 CHF outpatients. This methodological study was designed to define a clinically meaningful change in KCCQ scores, a 23-item disease-specific, patient-centered measure of health status outcomes. Baseline, 6-week, and 1-year follow-up data are currently available. • Clinical Trials databases: Dr. Spertus is frequently invited to contribute to the design and analysis of clinical trials. Since joining UMKC, he has actively participated in the design and analysis of the COURAGE, TACTICS/TIMI-18, EPHESUS, RELIANT and EVEREST trials. Often these datasets are available for additional analyses. • Prospective Registry Evaluating outcomes after Myocardial Infarction: Events and Recovery (PREMIER) QI Registry: This is a 19-center prospective registry of 2500 AMI patients and extends the INFORM project to a multi-center study. Understanding prevalence of angina after treatment, processes of AMI care, and feedback reports to sites to improve care are goals of this project. Baseline data available Fall 2004, with 1-month, 6-month, and 1-year follow-up data available Fall 2005. • Translation Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH): This is a 20-center prospective registry of 4,500 AMI patients expanding the PREMIER study to include lipid and genetic analysis on all patients. Beginning May 2005 and enrolling for 3 consecutive years, the racial differences in outcomes, care, lipid and genetic data will be collected and combined with in-depth follow-up at 1, 6, and 12-month time point data. • Patient-Refined Expectations for Deciding Invasive Cardiac Treatments (PREDICT): Funded by the Doris Duke Charitable Foundation, this project developed the computer informatics infrastructure for translating complex risk-adjustment models to the bedside of patient care. Future studies examining how best to implement and the impact of PREDICT on patients' outcomes are currently being developed. For more information: John A. Spertus, MD, MPH, FACC Director, Cardiovascular Education and Outcomes Research Mid America Heart Institute at Saint Luke's Hospital 4401 Wornall Road Kansas City, MO 64111 (816) 932-5475

Source: http://www.thehollandergroup.net/pos_desc_files/UMKC%20Hicklin%20Chair%20(October%202007).pdf